A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer ...

Substantial EFS improvement with selpercatinib in RET fusion-positive disease ...

Eli Lilly and Company (NYSE:LLY) announced positive data from its Phase 3 LIBRETTO-432 trial, showing that Retevmo significantly lowered the risk of disease recurrence or death in patients with ...

Surgery is a common treatment for non-small cell lung cancer (NSCLC), particularly when the disease is detected early and the tumor is small and is only in one part of the lung. For small cell lung ...

A new study co-led by investigators at UCLA has found a drug can reduce the risk of re-acquiring lung cancer, it was announced Sunday. Researchers at UCLA’s Health Jonsson Comprehensive Cancer Center ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...